H&T Presspart and Cohero Health have introduced a new fully-embedded and connected metered dose inhaler (eMDI) to optimize care of asthma and COPD.
The eMDI is incorporated with Cohero Health’s BreatheSmart respiratory disease management platform, which allows to track both controller and rescue medications along with clinically accurate lung function measurement in real-time.
The new inhaler helps patients to monitor themselves by tracking, recording and sharing data on the use of both preventer (controller) and reliever (rescue) medications.
Medication utilization data from the eMDI can be combined in real-time with lung function data from Cohero Health’s mSpirometer, a clinical grade handheld wireless spirometer that precisely measures critical lung function metrics.
Sensors embedded within the inhaler will help to track the date and time of medication use and the quality of delivery.
Both are recorded in onboard memory and shared wirelessly through Bluetooth to sync with BreatheSmart app that can offer customized reminders, real-time alerts and updates on medication usage, in addition to weekly and monthly summary reports.
The eMDI also integrates an FDA approved mechanical dose counter, helping pharma firms to passage current products to connected devices more easily and in a step-wise manner
H&T Presspart CEO Peter Schmelzer said: “In designing the eMDI, our mission was to help pharmaceutical companies bring the best possible care to patients in an intuitive device in the fastest time and most cost-efficient way.”
Cohero Health co-founder and CEO Mellissa Manice said: “In designing the eMDI, our mission was to help pharmaceutical companies bring the best possible care to patients in an intuitive device in the fastest time and most cost-efficient way.”
Image: The new connected metered dose inhaler for asthma and COPD patients. Photo: courtesy of Presspart Manufacturing Ltd.